The risks of continuing trastuzumab treatment in HER-2 positive breast cancer after the development of asymptomatic left ventricular dysfunction
Event:
Heart Failure 2024
Topic:
Cardio-Oncology
Session:
Cardiovascular disease in special populations - cardio-oncology (1)
